For example, K604-Gln-intact cancers could be sensitized to HU and ALS treatments through the Gln-K604 inhibitor glutaminol, whereas Gln-K604-null cancers could be sensitized by silencing c-MYC and MCL-1. This evidence concerns the gene MYC and amyotrophic lateral sclerosis.